So in general, really blinatumomab was very well tolerated. There were some more cytopenias in some of the patients with ...

The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the ...

Discover why Biogen Inc.'s stock surged 15% in 2025, driven by Skyclarys sales. Explore its strong growth potential and ...

Fact checked by Nick Blackmer Vitamin D directly supports immune health; vitamin E’s immune benefits are indirect and limited ...

Traveling at high altitude can be hazardous. The information provided here is designed for educational use only and is not a substitute for specific training or experience. Princeton University and ...

Spinocerebellar ataxia type 3 (SCA3) involves cerebellar, pyramidal, extrapyramidal, motor neuron and oculomotor systems with strong phenotypic heterogeneity, that lead us to classify the disorder ...

Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the company to lose more than 40% of their value in pre-market trading. The news is ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU. Skyclarys ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

Scientists discovered that certain gene changes allow cells to function even when frataxin, the protein lost in Friedreich’s ataxia, is missing. Experiments in worms, human cells, and mice revealed ...

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the ...